Efficacy of neoadjuvant atezolizumab treatment in patients with advanced urothelial bladder cancer according to the BASQ classification: a study protocol for an open-label, two-cohort, phase II trial

INTRODUCTION: Atezolizumab is a programmed death ligand-1 inhibitor for urothelial bladder cancer treatment. Atezolizumab has become the standard therapy for patients with urothelial bladder cancer who are not responding to cisplatin-based chemotherapy and is also used as a first-line treatment in c...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuk, Hyeong Dong, Jeong, Chang Wook, Kwak, Cheol, Kim, Hyeon, Moon, Kyung Chul, Ku, Ja Hyeon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Urology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7566723/
https://www.ncbi.nlm.nih.gov/pubmed/33060077
http://dx.doi.org/10.1136/bmjopen-2019-035530

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7566723/
https://www.ncbi.nlm.nih.gov/pubmed/33060077
http://dx.doi.org/10.1136/bmjopen-2019-035530

Ejemplares similares